Universidade Nova de Lisboa   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Lisbon Portugal (1973)

Organization Overview

First Clinical Trial
2015
NCT02492217
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CINTESIS - Center for Health Technology and Services Research, NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal | Faculdade de Ciências Médicas|NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal | NOVA Medical School | Faculdade de Ciências Médicas da Universidade NOVA de Lisboa | NOVA Medical School of Universidade NOVA de Lisboa | NOVA Medical School, Universidade Nova de Lisboa | Universidade Nova de Lisboa | Universidade Nova de Lisboa, Portugal

Active Ingredients

Drugs in Phase 4 Trials (1)

adalimumab (humira) (1 trial)

Drugs in Phase 2 Trials (1)

nivolumab (opdivo) (1 trial)

Drugs in Phase 1 Trials (1)

acetaminophen (tylenol) (1 trial)

Drugs in Other Trials (5)

3-[n-butyl-n-acetyl]-aminopropionic acid ethyl ester (1 trial)

apple (1 trial)

chestnut (1 trial)

hafnia alvei ha4597 (1 trial)

orange juice (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms, Germ Cell and Embryonal (Phase 2)

Spondylitis (Phase 4)

Spondylitis, Ankylosing (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 8